Core Viewpoint - HUTCHMED has initiated the Phase III part of a clinical trial to evaluate a combination therapy for metastatic pancreatic ductal adenocarcinoma (PDAC), which is a highly aggressive cancer with poor survival rates [1][2]. Group 1: Clinical Trial Details - The trial is a multicenter, randomized, open-label, active-controlled Phase II/III study assessing the efficacy and safety of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer who have not received prior systemic therapy [2]. - A total of 62 patients were enrolled in the Phase II part, with plans to enroll approximately 400 additional patients in the Phase III part [2]. - The primary endpoint for the Phase III part is overall survival (OS), while secondary endpoints include progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), quality of life, and safety [2]. Group 2: Phase II Results - As of July 24, 2025, the median PFS for the S+C+AG regimen was 7.20 months compared to 5.52 months for the AG arm, indicating a 50.1% reduction in the risk of progression or death [3]. - The ORR was 67.7% for the S+C+AG arm versus 41.9% for the AG arm, and the DCR was 93.5% compared to 71.0% for the AG arm [3]. - Although overall survival data were immature, a favorable trend was observed with 9 events in the S+C+AG arm and 15 events in the AG arm [3]. Group 3: Drug Information - Surufatinib is a novel oral angio-immuno kinase inhibitor that targets VEGFRs, FGFR, and CSF-1R, promoting the immune response against tumor cells [4]. - Camrelizumab is a humanized monoclonal antibody targeting the PD-1 receptor, approved in China for multiple cancer indications [5]. - HUTCHMED is an innovative biopharmaceutical company focused on the development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [6].